Bionomics Phase II Trial Affirms Renal Cancer Marker For Best Treatment
This article was originally published in PharmAsia News
Executive Summary
Australia's Bionomics reports a mid-stage trial of its BNC105 drug for renal cancer has enabled researchers to identify biomarkers pointing to the proper treatment for members of subgroups with the disease.